JP2017519502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519502A5 JP2017519502A5 JP2016573854A JP2016573854A JP2017519502A5 JP 2017519502 A5 JP2017519502 A5 JP 2017519502A5 JP 2016573854 A JP2016573854 A JP 2016573854A JP 2016573854 A JP2016573854 A JP 2016573854A JP 2017519502 A5 JP2017519502 A5 JP 2017519502A5
- Authority
- JP
- Japan
- Prior art keywords
- chain
- antigen receptor
- chimeric antigen
- specific multi
- fcεri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 13
- 102000009438 IgE Receptors Human genes 0.000 claims 7
- 108010073816 IgE Receptors Proteins 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 210000002865 immune cell Anatomy 0.000 claims 5
- 108020001756 ligand binding domains Proteins 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 101710185679 CD276 antigen Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- -1 ICOS Proteins 0.000 claims 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 108010065816 zeta chain antigen T cell receptor Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201470361 | 2014-06-17 | ||
| DKPA201470361 | 2014-06-17 | ||
| PCT/EP2015/063656 WO2015193406A1 (en) | 2014-06-17 | 2015-06-17 | Cd123 specific multi-chain chimeric antigen receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017519502A JP2017519502A (ja) | 2017-07-20 |
| JP2017519502A5 true JP2017519502A5 (Direct) | 2018-07-12 |
Family
ID=51062604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573854A Pending JP2017519502A (ja) | 2014-06-17 | 2015-06-17 | Ｃｄ１２３特異的多重鎖キメラ抗原受容体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180134795A1 (Direct) |
| EP (1) | EP3158064A1 (Direct) |
| JP (1) | JP2017519502A (Direct) |
| AU (1) | AU2015276131A1 (Direct) |
| CA (1) | CA2949325A1 (Direct) |
| WO (1) | WO2015193406A1 (Direct) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106103490B (zh) * | 2014-03-19 | 2020-03-03 | 塞勒克提斯公司 | 用于癌症免疫疗法的cd123特异性嵌合抗原受体 |
| WO2016149254A1 (en) | 2015-03-17 | 2016-09-22 | Chimera Bioengineering, Inc. | Smart car devices, de car polypeptides, side cars and uses thereof |
| US11052111B2 (en) * | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| US10222369B2 (en) | 2016-05-17 | 2019-03-05 | Chimera Bioengineering, Inc. | Methods for making novel antigen binding domains |
| MA45498A (fr) * | 2016-06-16 | 2019-04-24 | Memorial Sloan Kettering Cancer Center | Cellules treg génétiquement modifiées |
| CN107793481A (zh) * | 2016-08-31 | 2018-03-13 | 南京传奇生物科技有限公司 | 一种靶向人cd123的嵌合受体配体及其应用 |
| JP7045378B2 (ja) | 2016-09-01 | 2022-03-31 | キメラ・バイオエンジニアリング，インコーポレーテッド | Ｇｏｌｄ最適化ＣＡＲ Ｔ細胞 |
| AU2017338846B2 (en) * | 2016-10-04 | 2020-09-24 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
| EP3757133A4 (en) | 2018-02-11 | 2021-12-01 | Jiangsu Hengrui Medicine Co., Ltd. | ISOLATED ANTIGENIC CHEMICAL RECEPTOR, MODIFIED T LYMPHOCYTE INCLUDING IT AND ASSOCIATED USE |
| JP2021518747A (ja) | 2018-02-13 | 2021-08-05 | キメラ・バイオエンジニアリング，インコーポレーテッド | Ｒｎａ不安定化エレメントを使用した遺伝子発現の調整 |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| WO2021034653A1 (en) | 2019-08-18 | 2021-02-25 | Chimera Bioengineering, Inc. | Combination therapy with gold controlled transgenes |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CN116194575A (zh) * | 2020-06-22 | 2023-05-30 | 拉莫特特拉维夫大学有限公司 | 多亚基蛋白质组件、表达多亚基蛋白质组件的细胞及其用途 |
| WO2022144836A1 (en) | 2020-12-31 | 2022-07-07 | Sanofi | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| WO2023000036A1 (en) * | 2021-07-22 | 2023-01-26 | The Westmead Institute for Medical Research | Chimeric antigen receptor useful in treating cancer |
| US20250195658A1 (en) * | 2022-01-12 | 2025-06-19 | St. Jude Children's Research Hospital, Inc. | Bispecific chimeric antigen receptors targeting grp78 and cd123 or grp78 and b7h3 |
| EP4532023A1 (en) | 2022-05-27 | 2025-04-09 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| WO2024094004A1 (zh) * | 2022-11-03 | 2024-05-10 | 重庆精准生物技术有限公司 | 靶向cd123的全人源抗体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8163279B2 (en) * | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
| JP5694923B2 (ja) * | 2009-04-27 | 2015-04-01 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体 |
| EP2332994A1 (en) * | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SMT202200295T1 (it) * | 2012-05-18 | 2022-09-14 | Aptevo Res & Development Llc | Immunofusione bispecifica (bif) di scfv legante cd123 e cd3 |
| CN104769103B (zh) * | 2012-09-04 | 2018-06-08 | 塞勒克提斯公司 | 多链嵌合抗原受体和其用途 |
-
2015
- 2015-06-17 US US15/314,337 patent/US20180134795A1/en not_active Abandoned
- 2015-06-17 WO PCT/EP2015/063656 patent/WO2015193406A1/en not_active Ceased
- 2015-06-17 EP EP15730754.7A patent/EP3158064A1/en not_active Withdrawn
- 2015-06-17 AU AU2015276131A patent/AU2015276131A1/en not_active Abandoned
- 2015-06-17 CA CA2949325A patent/CA2949325A1/en not_active Abandoned
- 2015-06-17 JP JP2016573854A patent/JP2017519502A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519502A5 (Direct) | ||
| JP2017518071A5 (Direct) | ||
| FI4324851T3 (fi) | BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä | |
| JP2017522893A5 (Direct) | ||
| Sasidharan Nair et al. | Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells | |
| JP2020511136A5 (Direct) | ||
| JP2021087455A5 (Direct) | ||
| JP2017513478A5 (Direct) | ||
| JP2018508219A5 (Direct) | ||
| JP2020517295A5 (Direct) | ||
| JP2019527557A5 (Direct) | ||
| JP2017524367A5 (Direct) | ||
| JP2018525006A5 (Direct) | ||
| JP2019527537A5 (Direct) | ||
| JP2018504094A5 (Direct) | ||
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| HRP20231542T1 (hr) | Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe | |
| JP2020114264A5 (Direct) | ||
| JP2021500881A5 (Direct) | ||
| FI3703750T3 (fi) | B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja | |
| JP2020513754A5 (Direct) | ||
| JP2016520074A5 (Direct) | ||
| JP2015527070A5 (Direct) | ||
| IL275391B2 (en) | Antibodies binding ctla-4 and uses thereof | |
| FI3710067T3 (fi) | Polypeptidejä sisältävä d-domeeni ja niiden käyttötarkoitukset |